Examiner Rossi Julia A

1615-ROSSI-JULIA-A

Employment Information

Art Unit:1615 — Drug, bio-affecting and body treating compositions
Group:1610 — Pharmaceutical and Agricultural Compositions; Plant Growth Regulating Compositions: Bio-affecting, Body Treating, Drug Delivery, Steroids, Herbicides, Pesticides, Cosmetics, and Drugs; In vivo Diagnostic Agents
Classes: 424 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
435 — Chemistry: molecular biology and microbiology
504 — Plant protecting and regulating compositions
Phone:(571) 272-0138
Email:None
Location:None
Title:Pat Examnr Physics
Service:2 years
Grade:GS-09

Grant Rate and Difficulty Ranking

3-Year Grant rate: 0% over 6 cases
Difficulty: Not enough data to rank
Difficulty Percentile:

With Examiner Rossi, you have a 0% chance of getting an issued patent by 3 years after the first office action.

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Rossi, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1615

Examiner Rossi's grant rate is lower than that of Art Unit 1615 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Rossi 0.9
Art Unit 1615 1.8

Interview Benefit

Grant Rate without Interview

Examiner Rossi has granted 0 of 6 cases without any applicant-requested interviews for a grant rate of 0%.

Grant Rate with Interview

Examiner Rossi has granted 0 of 0 cases with at least one applicant-requested interview for a grant rate of 0%.

Interview Benefit

With Examiner Rossi, conducting an interview increases your chance of getting a patent granted by 100%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17772985 Compositions And Methods For Prophylaxis Of Hiv Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
17921158 Methods And Compositions Relating To Ionic Liquid Adjuvants Abandoned View
17627698 Method For Decreasing Adverse-Effects Of Interferon Abandoned View
18007701 Kappa Opioid Receptor Agonist-Therapeutic Antigen Binding Protein Conjugate (Ktac) Compounds Abandoned View
18011647 Cell Lines Secreting Alpha-Synuclein Targeting Antibodies, Progranulin And Prosaposin And A Complex Of Both, And Gdnf Abandoned View
17778394 Method For Extracting A Protein From A Precipitate And Method For Precipitating Impurities Patented View
17544522 Lewis Y Radioimmunotherapy For The Treatment Of Cancer Patented View
17917421 Immunogenic Composition Comprising An Antigenic Moiety And A Liposomal Formulation, Method Of Producing The Composition, The Composition For Use As A Medicament, In Particular For Use As A Vaccine Abandoned View
17917433 Compositions And Methods For Vaccination And The Treatment Of Infectious Diseases Abandoned View
17914734 T-Cell Modulatory Multimeric Polypeptides With Conjugation Sites And Methods Of Use Thereof Abandoned View
17726486 Preservative For In Vitro Diagnostic Reagent And Use Thereof Abandoned View
17177236 Method For Protein Purification Patented View
18054244 Prevention Of Visible Particle Formation In Parenteral Protein Solutions Abandoned View
18181437 Masp-2 And Masp-3 Inhibitors, And Related Compositions And Methods, For Treatment Of Sickle Cell Disease Abandoned View
17762854 Fusion Polypeptides Binding Antibody Fc Domains And Integrin And Methods Of Use Patented View
17633893 Use Of The Anti-P-Selectin Antibody Crizanlizumab For Treating Sickle Cell Nephropathy And Chronic Kidney Disease Associated With Sickle Cell Disease Abandoned View
17808319 Antibodies Against Lif And Uses Thereof Abandoned View
17917418 Frb Antibodies Patented View
18132052 High Affinity Il-2 Receptor Agonists And Immunosuppressants To Enhance Immune Tolerance Abandoned View
17607879 Anti-Galectin-9 Antibodies And Uses Thereof Abandoned View
17604928 Chemically Induced Protein Dimerization Systems Patented View
17634405 Therapeutic Peptides Abandoned View
18113413 Immune Antigen Specific Il-18 Immunocytokines And Uses Thereof Patented View
17625693 Anti-Serine Protease Inhibitor Kazal (Spik) Antibodies, Immunoconjugates, And Methods Of Use Patented View
18118971 Immunosuppressant In Combination With High Affinity Il-2 Receptor Agonists And Related Dosing Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.

Loading...